

Model	Study name	Subgroup within study	Statistics with study removed					Risk ratio (95% CI) with study removed						
			Point	Lower limit	Upper limit	Z-Value	p-Value	0.10	0.20	0.50	1.00	2.00	5.00	10.00
	Mease PJ et al., 2016	Ixekizumab	2.083	1.794	2.417	9.657	0.000					+		
	Mease PJ et al., 2015	Secukinumab	1.987	1.700	2.322	8.625	0.000					+		
	McInnes IB et al., 2015	Secukinumab	2.064	1.787	2.384	9.843	0.000					+		
	Mease PJ et al., 2014	Brodalumab	2.040	1.778	2.340	10.185	0.000					+		
	Ritchlin et al., 2014	Ustekinumab	2.036	1.770	2.342	9.957	0.000					+		
	McInnes IB et al., 2013	Ustekinumab	2.084	1.791	2.426	9.477	0.000					+		
	Gottlieb AB et al., 2009	Ustekinumab	2.007	1.750	2.302	9.975	0.000					+		
Random			2.042	1.786	2.335	10.460	0.000					+		

Suppl. Fig 3. Sensitivity analysis - One study removed at a time and its effect on the primary end point effect estimates.